David C Clark
CIK 1290061 · CHIEF FINANCIAL OFFICER · last filed 2020-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALTH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 200
WESTMINSTER, CO 80020
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Oblong, Inc. (OBLG) Delisted | CHIEF FINANCIAL OFFICER | 69 | $2.70 | $186 | $0 | 2 | 2020-07-02 |
| GLOW | CHIEF FINANCIAL OFFICER | 52,550 | $34.26 | $1.80M | $0 | 12 | 2019-05-06 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | VP, Finance | 0 | — | — | -$847.5K | 16 | 2012-09-05 |
Recent Filings · Page 2 of 3
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-02-06 | GLOW | Grant (A) | +80,000 | $83.2K | EDGAR |
| 2014-03-26 | GLOW | Tax (F) | −9,320 | -$16.9K | EDGAR |
| 2014-03-11 | GLOW | Grant (A) | +35,121 | $0 | EDGAR |
| 2013-03-27 | GLOW | Grant (A) | +100,000 | $0 | EDGAR |
| 2012-09-05 | ALLOS THERAPEUTICS INC (ALTH) Delisted | U | −207,114 | -$376.9K | EDGAR |
| 2012-03-01 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Mixed | +93,006 | -$10.2K | EDGAR |
| 2012-02-27 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Sell (S) | −2,055 | -$3.2K | EDGAR |
| 2011-11-17 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Sell (S) | −5,563 | -$8.0K | EDGAR |
| 2011-03-02 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Grant (A) | +53,957 | $0 | EDGAR |
| 2011-02-25 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Sell (S) | −1,922 | -$6.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.